

## Drug Monograph

Drug Name: **Epclusa® (velpatasvir/sofosbuvir) pellet pack**  
 Drug Class: **Anti-infectives: Hepatitis C Agents, Oral Direct-Acting Antivirals**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Epclusa is now available in a 200 mg/50 mg pellet pack and 150 mg/37.5 mg pellet pack.

**Manufacturer:** Manufactured by: Gilead Sciences, Inc., Foster City, CA 94404.

**Indications:** Epclusa is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, and 6 infection:

- Without cirrhosis or with compensated cirrhosis
- With decompensated cirrhosis for use in combination with ribavirin.

**Costs:** \$24,920 per 28 packs. Wholesale Acquisition Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

**Status Recommendation:**

<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
<input type="checkbox"/> Open Access	<input checked="" type="checkbox"/> PDL

**Type of PA Criteria:**

<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Non-Preferred
<input type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD  
 Date: December 30, 2021